Company

Acceleron Pharma Inc.

Headquarters: Cambridge, MA, United States

Founded: 2003 

Employees: 225

NASDAQ: XLRN

Market Cap

$10.56 Billion

USD as of Nov. 1, 2021

history Market Cap History

Acceleron Pharma Inc. market capitalization over time

Evolution of Acceleron Pharma Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Acceleron Pharma Inc.

Detailed Description

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Top 1-year algo backtest: +240.10%

$10,000 in February 2023 would now be $34,010 by following it 5 minutes per day at market close.

How much did you gain in the last 12 months?

Stocks & Indices

Acceleron Pharma Inc. has the following listings and related stock indices.


Stock: NASDAQ: XLRN wb_incandescent

Stock: FSX: 0A3 wb_incandescent

Key People

Habib Dable (CEO) Steve Ertel (COO) Matt Sherman (CMO) Kevin Mc Laughlin (CFO) Francois Nader (Chairman)

Financials

Revenue: $74.5 million for FY2017

Details

Headquarters:

128 Sidney Street

Cambridge, MA 02139

United States

Phone: 617 649 9200